BusinessDermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology CongressBy Nasdaq OMXOct 1, 2016, 7:05 AM UTC
BusinessDermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology CongressBy Nasdaq OMXSep 28, 2016, 11:30 AM UTC
BusinessGalectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced FibrosisBy Nasdaq OMXSep 27, 2016, 8:15 PM UTC
BusinessDermira Licenses DRM04 to Maruho for Hyperhidrosis in JapanBy Nasdaq OMXSep 20, 2016, 8:05 PM UTC
BusinessDermira Acquires Option to License Exclusive Rights for up to Three Early-Stage Programs from TakedaBy Nasdaq OMXSep 12, 2016, 11:30 AM UTC
BusinessGalectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment ConferenceBy Nasdaq OMXAug 31, 2016, 12:00 PM UTC
BusinessGalectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical TrialBy Nasdaq OMXAug 25, 2016, 12:00 PM UTC
BusinessDermira’s Co-founder and Chief Medical Officer, Eugene A. Bauer, M.D., Receives Presidential Citation from the American Academy of DermatologyBy Nasdaq OMXMar 14, 2016, 11:30 AM UTC
